FDA’s Compassionate Use Policy: Is Tysabri A Precedent Or A Special Case?
Executive Summary
When FDA stepped in and helped prominent trial lawyer and Democratic fundraiser Fred Baron get access to Tysabri for off-label treatment of his multiple myeloma, it raised questions about whether the agency had adopted a new policy
You may also be interested in...
FDA’s New Leadership May Be More Amenable To Expanded Access Programs
Patient activists say shift in Iplex case shows that the agency may begin to allow more compassionate use for products in development.
FDA Action On Off-Label Tysabri May Signal Policy Shift On Compassionate Use
FDA appears to be setting new policy on when drugs should be available for compassionate use
Abigail Alliance Presses For Access To Drugs With Troubled Regulatory Pasts
The Abigail Alliance's legal drama with FDA has ended, but the association continues to engage the agency on a number of products it wants to see offered through expanded access programs